Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in:

Open Access 18-12-2024 | Trastuzumab Deruxtecan | case report

Rare case of human epidermal growth factor receptor 2-positive gastric remnant cancer after bariatric surgery—case report

Authors: Carolin-Sophie Wagner, MD, Melanie Schartner, MD, Hermann Nehoda, MD, MSc, Peter P. Rainer, MD, PhD, Michael Schnallinger, MD

Published in: memo - Magazine of European Medical Oncology | Issue 1/2025

Login to get access

Summary

Parallel to the increasing number of patients with obesity and metabolic syndrome, the number of bariatric procedures is rapidly growing. Gastric bypass is the surgery of choice due to its high efficiency and safety profile; however, subsequent assessment and surveillance of the excluded stomach poses considerable challenges. Gastric remnant cancer is a rare entity and only a few cases have been published in the literature. Here, we report the first case of a human epidermal growth factor receptor 2-positive gastric cancer in the excluded remnant in a 58-year-old man with a history of bariatric Roux-en‑Y gastric bypass surgery. This case highlights the challenge of cancer surveillance in the eliminated stomach and chemotherapeutic treatment after bariatric surgery. Furthermore, we address the efficacy of trastuzumab deruxtecan as a second-line therapy in HER2-positive gastric cancer.
Literature
1.
Iwu CD, Iwu-Jaja CJ. Gastric Cancer Epidemiology: Current Trend and Future Direction. Hyg Nutr Foodserv Cater. 2023;3:256–68.
2.
Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71:264–79.CrossRefPubMed
3.
Van Cutsem E, Bang Y‑J, Feng-Yi F, Xu JM, Lee K‑W, Jiao S‑C, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18:476–84.CrossRefPubMed
4.
Shitara K, Bang Y‑J, Iwasa S, Sugimoto N, Ryu M‑H, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419–30.CrossRefPubMed
5.
Depotte L, Palle J, Rasola C, Broudin C, Afrăsânie V‑A, Mariani A, et al. New developments and standard of care in the management of advanced gastric cancer. Clin Res Hepatol Gastroenterol. 2024;48:102245.CrossRefPubMed
6.
Fink J, Seifert G, Blüher M, Fichtner-Feigl S, Marjanovic G. Obesity Surgery. Dtsch Ärztebl Int. 2022;119:70–80.PubMedPubMedCentral
7.
Chen Z‑W, Jin T, Liang P‑P, Li Z‑D, He F‑J, Chen Z‑H, et al. Incidence of cancer for patients after bariatric surgery: evidence from 33 cohort studies. Surg Obes Relat Dis. 2024;20:467–81.CrossRefPubMed
8.
Liao J, Yin Y, Zhong J, Chen Y, Chen Y, Wen Y, et al. Bariatric surgery and health outcomes: An umbrella analysis. Front Endocrinol (lausanne). 2022;13:1016613.CrossRefPubMed
9.
Doukas SG, Doukas PG, Vageli DP, Broder A. Gastric cancer after Bariatric Bypass Surgery. Do they relate? (A Systematic Review). OBES SURG. 2023;33:1876–88.CrossRefPubMed
10.
Lazzati A, Poghosyan T, Touati M, Collet D, Gronnier C. Risk of esophageal and gastric cancer after bariatric surgery. JAMA Surg. 2023;158:264–71.CrossRefPubMedPubMedCentral
11.
12.
Cortés J, Kim S‑B, Chung W‑P, Im S‑A, Park YH, Hegg R, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386:1143–54.CrossRefPubMed
13.
14.
Wilke H, Muro K, Van Cutsem E, Oh S‑C, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35.CrossRefPubMed
15.
Zhang C, Xiang Y, Wang J, Yan D. Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis. Front Oncol. 2023;13:1118820.CrossRefPubMedPubMedCentral
16.
Liu D, Kou F, Gong J, Wang Z, Zhang X, Li J, et al. Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: A dose-escalation phase I study. Cancer Med. 2023;12:10704–14.CrossRefPubMedPubMedCentral
17.
Lakhani NJ, Chow LQM, Gainor JF, LoRusso P, Lee K‑W, Chung HC, et al. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021;22:1740–51.CrossRefPubMed
18.
Pavlakis N, Shitara K, Sjoquist K, Martin A, Jaworski A, Tebbutt N, et al. INTEGRATE IIa phase III study: Regorafenib for refractory advanced gastric cancer. J Clin Oncol.2024:JCO2400055.
19.
Chen L‑T, Satoh T, Ryu M‑H, Chao Y, Kato K, Chung HC, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2‑year update data. Gastric Cancer. 2019;23:510–9.CrossRefPubMedPubMedCentral
20.
Li J, Qin S, Wen L, Wang J, Deng W, Guo W, et al. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study. BMC Med. 2023;21:173.CrossRefPubMedPubMedCentral
Metadata
Title
Rare case of human epidermal growth factor receptor 2-positive gastric remnant cancer after bariatric surgery—case report
Authors
Carolin-Sophie Wagner, MD
Melanie Schartner, MD
Hermann Nehoda, MD, MSc
Peter P. Rainer, MD, PhD
Michael Schnallinger, MD
Publication date
18-12-2024
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2025
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-024-01007-2

Other articles of this Issue 1/2025

Personalized decision making of neoadjuvant chemotherapy vs. upfront surgery in pancreatic cancer by a simple blood collection?

Highlights on gastroesophageal tumors: the comeback of FLOT

Unclassifiable acute leukemia with blastic plasmacytoid dendritic cell neoplasm: deciding on the appropriate therapy

Placement of port-a-cath systems via the jugular vein: a surgical perspective

Implantable catheter chambers: a 14-year descriptive study

  • original report

Local treatment strategies in oligometastatic colorectal cancer

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Video
Image Credits